The stock of Cara Therapeutics Inc. (CARA) has gone up by 21.88% for the week, with a -20.14% drop in the past month and a -27.55% drop in the past quarter. The volatility ratio for the week is 12.04%, and the volatility levels for the past 30 days are 7.78% for CARA. The simple moving average for the past 20 days is -5.65% for CARA’s stock, with a -62.00% simple moving average for the past 200 days.
Is It Worth Investing in Cara Therapeutics Inc. (NASDAQ: CARA) Right Now?
while the 36-month beta value is 0.88.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price point forecasted by analysts for Cara Therapeutics Inc. (CARA) is $15.50, which is $13.09 above the current market price. The public float for CARA is 46.14M, and currently, short sellers hold a 3.36% ratio of that floaft. The average trading volume of CARA on September 18, 2023 was 1.31M shares.
CARA) stock’s latest price update
The stock price of Cara Therapeutics Inc. (NASDAQ: CARA) has jumped by 13.04 compared to previous close of 2.07. Despite this, the company has seen a gain of 21.88% in its stock price over the last five trading days. Zacks Investment Research reported 2023-08-07 that Cara Therapeutics (CARA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.08 per share a year ago.
Analysts’ Opinion of CARA
Many brokerage firms have already submitted their reports for CARA stocks, with BofA Securities repeating the rating for CARA by listing it as a “Underperform.” The predicted price for CARA in the upcoming period, according to BofA Securities is $6 based on the research report published on March 08, 2023 of the current year 2023.
CARA Trading at -15.53% from the 50-Day Moving Average
After a stumble in the market that brought CARA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.73% of loss for the given period.
Volatility was left at 7.78%, however, over the last 30 days, the volatility rate increased by 12.04%, as shares sank -22.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.65% lower at present.
During the last 5 trading sessions, CARA rose by +21.87%, which changed the moving average for the period of 200-days by -78.98% in comparison to the 20-day moving average, which settled at $2.45. In addition, Cara Therapeutics Inc. saw -78.21% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CARA starting from Posner Christopher, who sale 4,307 shares at the price of $3.07 back on Aug 03. After this action, Posner Christopher now owns 168,207 shares of Cara Therapeutics Inc., valued at $13,222 using the latest closing price.
Menzaghi Frederique Ph.D., the Chief Scientific Off,SVP-R&D of Cara Therapeutics Inc., sale 2,993 shares at $3.51 during a trade that took place back on Jun 23, which means that Menzaghi Frederique Ph.D. is holding 153,747 shares at $10,505 based on the most recent closing price.
Stock Fundamentals for CARA
Current profitability levels for the company are sitting at:
- -209.08 for the present operating margin
- +82.05 for the gross margin
The net margin for Cara Therapeutics Inc. stands at -204.16. The total capital return value is set at -44.67, while invested capital returns managed to touch -44.03. Equity return is now at value -75.80, with -65.40 for asset returns.
Based on Cara Therapeutics Inc. (CARA), the company’s capital structure generated 1.21 points at debt to equity in total, while total debt to capital is 1.19.
When we switch over and look at the enterprise to sales, we see a ratio of -0.64, with the company’s debt to enterprise value settled at 0.00. The receivables turnover for the company is 14.94 and the total asset turnover is 0.20. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.20.
Conclusion
In a nutshell, Cara Therapeutics Inc. (CARA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
